Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience.
Liver cancer is the sixth most common cancer worldwide in terms of the number of cases (626,000 or 5.7% of new cancer cases) but due to the very poor prognosis, the number of deaths is nearly similar (598,000). The survival rate is 3% to 5% in cancer registries for the United States and developing...
Main Authors: | Ilirian Laçi, Alketa Spahiu |
---|---|
Format: | Article |
Language: | English |
Published: |
Albanian Society for Trauma and Emergency Surgery
2022-07-01
|
Series: | Albanian Journal of Trauma and Emergency Surgery |
Subjects: | |
Online Access: | http://journal.astes.org.al/index.php/AJTES/article/view/291 |
Similar Items
-
Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma
by: Yi-Sheng Liu, et al.
Published: (2018-08-01) -
Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3–7 cm
by: Yashwant Patidar, et al.
Published: (2019-01-01) -
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-02-01) -
Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization
by: Jing-Xuan Xu, et al.
Published: (2023-12-01) -
Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Jun-Ning Liu, et al.
Published: (2023-06-01)